MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ
15.96
-0.77
-4.60%
After Hours: 15.96 0 0.00% 19:18 01/08 EST
OPEN
16.52
PREV CLOSE
16.73
HIGH
16.81
LOW
15.53
VOLUME
2.07M
TURNOVER
--
52 WEEK HIGH
20.76
52 WEEK LOW
5.98
MARKET CAP
2.44B
P/E (TTM)
-29.6599
1D
5D
1M
3M
1Y
5Y
1D
Assessing Adaptive Biotechnologies (ADPT) Valuation After New Pfizer Deals And Digital Biotechnologies Financing
Simply Wall St · 5h ago
Adaptive Biotechnologies Chief Scientific Officer Harlan S. Robins Reports Sale of Common Shares
Reuters · 10h ago
CEO and Chairman Chad M. Robins Reports Sale of Adaptive Biotechnologies Common Shares
Reuters · 1d ago
Adaptive Biotechnologies price target raised to $20 from $19 at TD Cowen
TipRanks · 1d ago
Chief People Officer Francis Lo Reports Sale of Adaptive Biotechnologies Common Shares
Reuters · 2d ago
Weekly Report: what happened at ADPT last week (1229-0102)?
Weekly Report · 4d ago
Adaptive Biotechnologies to Present at J.P. Morgan Healthcare Conference
Reuters · 12/30/2025 21:05
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
Barchart · 12/30/2025 15:05
More
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.

Webull offers Adaptive Biotechnologies Corp stock information, including NASDAQ: ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADPT stock methods without spending real money on the virtual paper trading platform.